

**Amendments to the Claims:**

Claim 1 (cancelled)

2. (Currently amended) A method for treating donor cells to ameliorate graft versus host disease in a recipient patient comprising:

- a) removing peripheral blood mononuclear cells (PBMC) from a donor;
- b) treating said PBMC with a suppressive-inducing composition comprising TGF- $\beta$ , IL-2, and at least one other T cell activator for a time sufficient to induce T cell tolerance in said patient; and
- c) introducing said treated PBMC to said patient.

Claims 3-4 (Cancelled)

5. (Withdrawn) A method according to claim [[4]] 2, wherein said other T cell activator is a recipient cell.

6. (Original) A method according to claim 2 wherein said method further comprises adding said cells to donor stem cells prior to introduction into said patient.

7. (Withdrawn) A method according to claim [[1 or]] 2 wherein said PBMC[[s]] are enriched for CD8+ cells.

8. (Withdrawn) A method according to claim [[1 or]] 2 wherein said PBMC[[s]] are enriched for CD4+ cells.

Claim 9 (cancelled)

10. (Currently amended) A method for treating donor cells to ameliorate graft versus host disease in a recipient patient comprising:

- a) removing peripheral blood mononuclear cells (PBMC) from a donor;
- b) treating said PBMC with a suppressive-inducing composition comprising TGF- $\beta$ , IL-2, and at least one other T cell activator for a time sufficient to generate suppressor cells; and
- c) introducing said suppressor cells to said patient.

Claims 11-13 (Cancelled)

14. (Withdrawn) A method according to claim [[13]] 10, wherein said other T cell activator is a recipient cell.

15. (Original) A method according to claim 10 wherein said method further comprises adding said cells to donor stem cells prior to introduction into said patient.

16. (Withdrawn) A method according to claim [[9 or]] 10, wherein said PMBC[[s]] are enriched for CD8+ cells.

17. (Withdrawn) A method according to claim [[9 or]] 10, wherein said PMBC[[s]] are enriched for CD4+ cells.

Claims 18-28 (cancelled)

29. (Previously presented) A method according to claim 2 wherein said PBMC are enriched for CD3+CD4-CD8- cells.

30. (Previously presented) A method according to claim 10 wherein said PBMC are enriched for CD3+CD4-CD8- cells.

31. (Currently amended) A method for treating donor cells to ameliorate graft versus host disease in a recipient patient comprising:

- a) removing peripheral blood mononuclear cells (PBMC) from a donor;
- b) selectively enriching said PBMC for CD3+CD4-CD8- cells;
- c) treating said CD3+CD4-CD8- cells with a suppressive-inducing composition comprising TGF- $\beta$ , IL-2 and at least one other T cell activator for a time sufficient to induce T cell tolerance in said patient; and
- c) introducing said treated CD3+CD4-CD8- cells to said patient.

32. (Currently amended) A method for treating donor cells to ameliorate graft versus host disease in a recipient patient comprising:

- a) removing peripheral blood mononuclear cells (PBMC) from a donor;
- b) selectively enriching said PBMC for CD3+CD4-CD8- cells;
- c) treating said CD3+CD4-CD8- cells with a suppressive-inducing composition comprising TGF- $\beta$ , IL-2 and at least one other T cell activator for a time sufficient to generate suppressor cells; and
- c) introducing said suppressor cells to said patient.

33. (Currently amended) A method according to claim 2, 10, 31 and 32 wherein said other T cell activator is anti-CD3.

34. (Withdrawn) A method according to claim [[4]] 2, 10, 31 and 32 wherein said other T cell activator is anti-CD28.

35. (Withdrawn) A method according to claim [[4]] 2, 10, 31 and 32 wherein said other T cell activator is anti-CD2.

36. (Withdrawn) A method according to claim [[4]] 2, 10, 31 and 32 wherein said other T cell activator is staphylococcus enterotoxin B.

Claims 37-40 (Cancelled)

41. (Previously presented) A method for treating donor cells to ameliorate graft versus host disease in a recipient patient comprising:
- a) removing peripheral blood mononuclear cells (PBMC) from a donor;
  - b) selectively enriching said PBMC for CD3+CD4-CD8- cells;
  - c) treating said CD3+CD4-CD8- cells with a suppressive-inducing composition comprising TGF- $\beta$ , IL-2 and the T cell activator anti-CD3 for a time sufficient to induce T cell tolerance in said patient; and
  - c) introducing said treated CD3+CD4-CD8- cells to said patient.
42. (Previously presented) A method for treating donor cells to ameliorate graft versus host disease in a recipient patient comprising:
- a) removing peripheral blood mononuclear cells (PBMC) from a donor;
  - b) selectively enriching said PBMC for CD3+CD4-CD8- cells;
  - c) treating said CD3+CD4-CD8- cells with a suppressive-inducing composition comprising TGF- $\beta$ , IL-2 and the T cell activator anti-CD3 for a time sufficient to generate suppressor cells; and
  - c) introducing said suppressor cells to said patient.